Dr. Shishir Seth

About Doctor

Click to Expand

Brief About Dr. Shishir Seth

Dr. Shishir Seth is a well-known hematologist who has been in practice for over 15 years. In addition, over the course of his career, he also has performed 190 hematopoietic BMTs with 40% of them being allogenic, including Haplo-identical and also antigen mismatch transplants.

Meanwhile, he has completed 390 acute leukemia induction treatments. Moreover, he is also passionate about research and has multiple publications in national and also international journals to his name.

In the meanwhile, Do read our Blog on All you should know about Thalassemia

Also, read 7 Things You Need to Know About Bone Marrow Transplants

Clinical Interests

Acute Leukaemia (AML/ ALL)
Lymphoma
Multiple Myeloma
Chronic Myelomonocytic Leukemia (CML)
CLL
Chronic Myeloproliferative Neoplasm
Myelodysplastic syndrome as well as anemia
Thalassemia
Bleeding and clotting disorders

Member of Associations

Life Member of the Indian Society of Haematology and also Transfusion Medicine
Member of American Society of Clinical Oncology
American Society of Haematology.

Paper Publications

Associated with research and also has several publications to his credit in noted national and international journals. These are the unusual presentations of pediatric acute lymphoblastic leukemia. Indian J Hematol Blood Transfuse, 2008; 24(2) 59-62
“Lymph node and Tuberculosis: Clinical, Pathological and Microbiological Correlation.” In CYTOCON-2003 at Pune, India
“Spectrum of small intestinal lymphoma in western India” in International conference on emerging trends in hematology and Immuno-hematology at Mumbai, India
“Chronic Myeloid Leukaemia: Demographic and clinical profile from a tertiary center in western India” in Leukaemias: molecular insights to treatment paradigms at Mumbai.
Hematopoietic Cell Transplantation in Lymphoma: Why & When; Evidence-Based Review. Cancer News, Dec 2011; 5(5) 10-12
Acute Myeloid Leukaemia- An Update, RGCI Newsletter-External- Mar 2012; 16(3) 2-3
Also, additional research, 2010DRL001, was also launched by an investigator to examine the response rate and toxicity (safety) associated with BR/bendamustine in newly diagnosed adult patients with chronic lymphocytic leukemia.
Principal Investigator for IVPL_RT_01: A study of Rituximab in patients with Non-Hodgkin’s Lymphoma a type of cancer.